Cancer Archives

News and Trends 26 Oct 2016

Can this new Antibody-Drug Conjugate Collaboration make it to the Top?

Nordic Nanovector is collaborating with Heidelberg Pharma to access the promising antibody-drug conjugate (ADC) technology. However, can it really take on the strong competition? Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat Non-Hodgkin Lymphoma (NHL) and other blood cancers. Today, the company has announced a collaboration with Wilex’ subsidiary Heidelberg Pharma to incorporate antibody-drug conjugates (ADCs) […]

October 26, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Oct 2016

The ‘First and Only’ Metastatic Lung Cancer Immunotherapy is approved

Roche’s Genentech has received FDA approval for an immunotherapy targeting the highly sought-after PD-L1. The treatment may be able to outperform its competitors in lung cancer therapies. In May, Roche received approval for Tecentriq (atezolizumab) in bladder cancer. Now, the drug is expanding its indications to become the first and only cancer immunotherapy in the market to target […]

October 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Oct 2016

And the highest funding in Europe this year goes to… Antibody-Drug Conjugates!

AstraZeneca has contributed to ADC Therapeutics’ €96M fundraising, the biggest round so far in Europe this year. Will this huge investment pay out for the British-Swedish Big Pharma? ADC Therapeutics (ADCT) is a Swiss Biotech that develops antibody-drug conjugates (ADCs) for oncology applications. Its founder Auven Therapeutics and its partner AstraZeneca have participated in the biggest […]

October 19, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Oct 2016

Shire’s leading Pancreatic Cancer drug is Back with a Bang

Pancreatic cancer is one of the nastiest kinds and most difficult to treat; the EMA has granted marketing authorization to Onivyde in the fight against it. Pancreatic cancer is the fourth-leading cause of death in Europe, and it represents a dramatically underserved need. Metastatic adenocarcinoma is almost always fatal, as it cannot be removed surgically […]

October 18, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 18 Oct 2016

€4M Grant for a Cancer Vaccine that could Bench its Competitors

Hookipa just secured a huge grant from the Austrian government. The plan is to develop the strongest HPV vaccine ever and claim its place in the €2B head and neck cancer market. Hookipa, one of the hottest Biotechs in Vienna, develops vaccines based on a new class of viral vectors. Its platform has impressed the public sector and secured €4.16M from the Austrian […]

October 18, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Oct 2016

It’s not over yet for Opdivo; AbbVie takes a stand in Leukemia

The Committee on Medicinal Products for Human Use (CHMP) has handed down a pair of positive opinions of Opdivo and AbbVie’s leukemia therapy in their quests for EMA approval. Before the European Commission reviews an application for market authorization, it crosses the collective desk of the Committee on Medicinal Products for Human Use (CHMP). If […]

October 17, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 13 Oct 2016

Adaptimmune Revises TCR Protocol following Phase I/IIa Failure

Shares of Adaptimmune slid 12% yesterday morning after the company updated its TCR therapy to include fludarabine, which was linked to deaths in Juno’s CAR-T trials. Despite optimism that T-cells are the key to cancer cures, the field has taken a number of hits this year. Most recently, the FDA put a partial hold on […]

October 13, 2016 - 2 minutesmins - By Evelyn Warner

Screenshot 2016 10 12 at 12.23.30 PM e1476267908354

News and Trends 12 Oct 2016

Transgene teams up with big Players against HPV Head and Neck Cancer

Transgene is partnering with Merck and Pfizer to develop a combined therapy for head and neck cancer squamous cell carcinoma (HNSCC) caused by human papiloma virus (HPV) infections. A successful outcome will let the team access a €2B market niche. Transgene has been struggling for a while: last year it had to fire 40% of its workforce […]

October 12, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Oct 2016

Will Aprea live up to the Hype of its €46M fundraising?

Aprea raised a huge €46M for a first-in-class drug that targets the deadliest form of ovarian cancer. The company just started Phase II trials after positive results from Phase I. But will it be able to outperform all its competitors? Aprea is a spin-out company from the Karolinska Development, the portfolio company of the Institute, in Sweden. It became […]

October 12, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Oct 2016

UK Upstart to sign Huge Deal with Takeda in End Run around Antibody Therapies

Crescendo Biologics, a small UK-based startup, has made an almost €1B deal with Japanese giant Takeda for its Humabody technology. Crescendo Biologics may seem like a small fish, but it has caught the attention of a host of blue-chip investors like Sofinnova Partners. Its Humabody platform has recently attracted the Japanese pharmaceutical giant, Takeda, whose subsidiary, […]

October 11, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 10 Oct 2016

Big Pharmas Battle to be the Lung Cancer Leader at ESMO

Merck, Roche and BMS have unveiled updated results in Copenhagen as the companies duke it out for the leadership in lung cancer therapies. The conference of the European Society of Medical Oncology (ESMO) is underway in Copenhagen, and big pharma’s efforts to cure lung cancer are stealing the show. Three titans, Roche (Genentech), Merck and […]

October 10, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 10 Oct 2016

Overseas Deaths in the Clinic come as a Blow to Boehringer Ingelheim

Boehringer Ingelheim has swiftly dumped its olmutinib collaboration with Hanmi following news of deaths in South Korean Phase II trials. An investigation by the South Korean Ministry of Food and Drug Safety has linked several deaths to olmutinib, a lung cancer drug launched by Hanmi. Sound familiar? Boehringer Ingelheim just signed a deal to acquire the […]

October 10, 2016 - 2 minutesmins - By Evelyn Warner

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Can this new Antibody-Drug Conjugate Collaboration make it to the Top?

The ‘First and Only’ Metastatic Lung Cancer Immunotherapy is approved

And the highest funding in Europe this year goes to… Antibody-Drug Conjugates!

Shire’s leading Pancreatic Cancer drug is Back with a Bang

€4M Grant for a Cancer Vaccine that could Bench its Competitors

It’s not over yet for Opdivo; AbbVie takes a stand in Leukemia

Adaptimmune Revises TCR Protocol following Phase I/IIa Failure

Transgene teams up with big Players against HPV Head and Neck Cancer

Will Aprea live up to the Hype of its €46M fundraising?

UK Upstart to sign Huge Deal with Takeda in End Run around Antibody Therapies

Big Pharmas Battle to be the Lung Cancer Leader at ESMO

Overseas Deaths in the Clinic come as a Blow to Boehringer Ingelheim

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!